Vitamin D Signaling in Inflammation and Cancer: Molecular Mechanisms and Therapeutic Implications
- PMID: 32679655
- PMCID: PMC7397283
- DOI: 10.3390/molecules25143219
Vitamin D Signaling in Inflammation and Cancer: Molecular Mechanisms and Therapeutic Implications
Abstract
Vitamin D and its active metabolites are important nutrients for human skeletal health. UV irradiation of skin converts 7-dehydrocholesterol into vitamin D3, which metabolized in the liver and kidneys into its active form, 1α,25-dihydroxyvitamin D3. Apart from its classical role in calcium and phosphate regulation, scientists have shown that the vitamin D receptor is expressed in almost all tissues of the body, hence it has numerous biological effects. These includes fetal and adult homeostatic functions in development and differentiation of metabolic, epidermal, endocrine, neurological and immunological systems of the body. Moreover, the expression of vitamin D receptor in the majority of immune cells and the ability of these cells to actively metabolize 25(OH)D3 into its active form 1,25(OH)2D3 reinforces the important role of vitamin D signaling in maintaining a healthy immune system. In addition, several studies have showed that vitamin D has important regulatory roles of mechanisms controlling proliferation, differentiation and growth. The administration of vitamin D analogues or the active metabolite of vitamin D activates apoptotic pathways, has antiproliferative effects and inhibits angiogenesis. This review aims to provide an up-to-date overview on the effects of vitamin D and its receptor (VDR) in regulating inflammation, different cell death modalities and cancer. It also aims to investigate the possible therapeutic benefits of vitamin D and its analogues as anticancer agents.
Keywords: carcinogenesis; cell death; inflammation immunomodulation; signaling pathways; therapeutic implications; vitamin D.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Vitamin D and systemic cancer: is this relevant to malignant melanoma?Br J Dermatol. 2002 Aug;147(2):197-213. doi: 10.1046/j.1365-2133.2002.04960.x. Br J Dermatol. 2002. PMID: 12174089 Review.
-
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.Nat Rev Cancer. 2007 Sep;7(9):684-700. doi: 10.1038/nrc2196. Nat Rev Cancer. 2007. PMID: 17721433 Review.
-
Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.Rev Endocr Metab Disord. 2016 Sep;17(3):405-417. doi: 10.1007/s11154-016-9353-4. Rev Endocr Metab Disord. 2016. PMID: 27447175 Review.
-
The anti-cancer actions of vitamin D.Anticancer Agents Med Chem. 2013 Jan;13(1):126-39. Anticancer Agents Med Chem. 2013. PMID: 23094926 Review.
-
[Bone and calcium metabolism associated with malignancy. Vitamin D and cancer.].Clin Calcium. 2018;28(11):1465-1472. Clin Calcium. 2018. PMID: 30374002 Japanese.
Cited by
-
Does vitamin D deficiency affect functional outcomes in hip fracture patients? A meta-analysis of cohort studies.J Endocrinol Invest. 2024 Jun;47(6):1323-1334. doi: 10.1007/s40618-023-02266-2. Epub 2023 Dec 19. J Endocrinol Invest. 2024. PMID: 38112912 Review.
-
Vitamin D in liver cancer: novel insights and future perspectives.Croat Med J. 2022 Apr 30;63(2):187-196. doi: 10.3325/cmj.2022.63.187. Croat Med J. 2022. PMID: 35505652 Free PMC article. Review.
-
Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review.Front Immunol. 2023 Jul 14;14:950465. doi: 10.3389/fimmu.2023.950465. eCollection 2023. Front Immunol. 2023. PMID: 37520529 Free PMC article. Review.
-
Vitamin D, Th17 Lymphocytes, and Breast Cancer.Cancers (Basel). 2022 Jul 27;14(15):3649. doi: 10.3390/cancers14153649. Cancers (Basel). 2022. PMID: 35954312 Free PMC article. Review.
-
The metabolic role of vitamin D in children's neurodevelopment: a network study.Sci Rep. 2024 Jul 23;14(1):16929. doi: 10.1038/s41598-024-67835-8. Sci Rep. 2024. PMID: 39043876 Free PMC article.
References
-
- D’Amelio P., Cristofaro M.A., De Vivo E., Ravazzoli M., Grosso E., Di Bella S., Aime M., Cotto N., Silvagno F., Isaia G.C., et al. Platelet vitamin D receptor is reduced in osteoporotic patients. Panminerva Med. 2012;54:225–231. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical